SEC Tracker
Get the app

Rapport Therapeutics RAPP

Rapport Therapeutics reports Q3 2026 financials and business updates

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Positive Phase 2 results for RAP-219 in bipolar mania with 3.1-point improvement in YMRS score
  2. Company has $815.4 million in cash and cash equivalents as of November 3, 2026
  3. Plans to initiate two Phase 3 trials for RAP-219 in bipolar mania in 2H 2027
  4. Net loss for Q3 2026 was $40.2 million

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Rapport Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  2. Ocugen OCGN public float $279M, Jun 30, 2025
  3. Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025
  4. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  5. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025